The present invention relates to an endograft device (101) for treatment of ruptures (104.9) in one or more inner layers of a blood vessel (104), in particular, an aorta, comprising an anchoring unit (101.1) and a sleeve unit (101.2). The endograft device (101) defines an upstream endograft end (101.3) and a downstream endograft end (101.4), upstream and downstream being defined, in an implanted state of the endograft device (101), in relation to a general natural blood flow defining a blood flow direction within the blood vessel (104). The anchoring unit (101.1) is a collapsible unit located at the upstream endograft end (101.3), wherein the anchoring unit (101.1) is configured to anchor, in the implanted state, the endograft device (101) within the blood vessel (104) by engaging an inner surface of the blood vessel (104) with an expanded anchoring section (101.5). The sleeve unit (101.2) is located downstream of the anchoring unit (101.1), wherein the sleeve unit (101.2) is a thin-walled foldable element defining a longitudinal direction, a radial direction, a circumferential direction, an upstream sleeve unit end (101.7) and a upstream sleeve unit end (101.8). The sleeve unit (101.2) comprises an unsupported section (101.9) located at the upstream sleeve unit end (101.7), wherein the unsupported section (101.9) extends along the longitudinal direction and, at least in the implanted state, is unsupported over its entire circumference. The sleeve unit (101.2) is configured to be expanded, in the implanted state, to rest against an inner wall of the blood vessel (104) to sealingly cover the rupture (104.9) with the unsupported section (101.9).

A tissue scaffold implant for expanding a stenotic lumen is provided that includes a bridge structure defining at least two angled sides and a lateral anchor integrally formed with the bridge structure. The lateral anchor is configured to be disposed against at least a portion of an external circumference of the stenotic lumen in a region near an opening formed in the stenotic lumen. At least two seat regions are defined between the at least two angled sides of the bridge structure and the lateral anchor. The at least two seat regions are configured to be received within and support the opening within the stenotic lumen, and the bridge structure and lateral anchor comprise a bioacceptable material.

Stents formed from dissimilar materials configured to control tissue growth. A stent may be formed from a composite wire helically wound into a stent having a tubular configuration. The composite wire includes a first wire and a second wire coupled together, the first and second wires being formed from dissimilar metals such that a potential difference is formed when the dissimilar metals are exposed to bodily fluids. The potential difference is configured to inhibit cell proliferation and thereby control tissue growth around the stent after implantation. A stent may be formed from a hollow composite wire including an inner member that includes first and second longitudinal strips formed from dissimilar metals. A stent may be formed from a composite wire having a plurality of windows along a length of the composite wire. An insert formed from a dissimilar metal is disposed within each window of the plurality of windows.

A prosthesis, left in the patient's heart to repair the tricuspid or mitral valve, is made to simultaneously hold all three tricuspid valve flaps, or the two mitral valve flaps, to keep them fully extended in the plane of the valve and to assume a final configuration as in the common surgical procedure. A device for repairing a tricuspid or mitral valve including such a prosthesis is also disclosed.

A degradable biomedical magnesium alloy drug-eluting vascular stent and a preparation method. With the total weight of a magnesium alloy being 100% for calculation, the magnesium alloy comprises the following components in percentage by weight: 3.0-6.0% of Gd, 2.5-5.5% of Y, 1.0-3.0% of Li, 0.3-1.0% of Zn, 0.2-1.0% of Zr, and the balance being Mg. The stent has good radial support strength and strain dispersion capability by means of finite element design. After a protective coating is used, the corrosion resistance of the magnesium alloy stent is greatly improved. An arsenic trioxide/rapamycin and tacrolimus composite drug sustained-release system is used to fully adapt to the damage repair process of blood vessels. An implantation result of large animals shows that the vascular stent system has a good anti-restenosis treatment effect.

The present invention concerns a medical device which can be used to prevent the obstruction of a body lumen, such as the urethra. Advantageously, the stent can be inserted after a surgical procedure to reduce stricture and because the stent is bioabsorbable, a second surgery can be avoided to remove the stent once it has fulfilled its function. The stent comprises a polymeric material prepared by co-polymerization of -caprolactone, -decalactone, -valerolactone, ethylene brassylate, or -hexalactone with lactide.

Stents or scaffolds made from magnesium or magnesium alloys including additives or barrier coatings that modify the corrosion rate of the stent are disclosed. Methods of forming barrier coatings that modify the corrosion rate of the stent are disclosed.

Implantable medical devices that contain at least one region that is selectively degradable by electrolytic corrosion are provided. The electrolytic corrosion of the medical device is initiated by the formation of an electrolytic cell that can be activated wirelessly at a designated point in time. The medical device incorporates at least one section or region that is designed to be predisposed to structural failure. The medical device contains a cathode region, a sacrificial anode region, which will undergo degradation, and an antenna region. Electrolytic degradation of a sacrificial anode region may cause a de-anchoring of the medical device or a reconfiguration of the medical device from a first configuration to a second configuration. Alternatively, electrolytic degradation may precipitate the absorption of the medical device. In another embodiment, electrolytic protection may be employed to preserve an implanted device until such a time that its corrosion and subsequent absorption is desired.

A split type precisely-anchorable transcatheter valve-in-ring system comprises a split transcatheter valve-in-ring anchoring stent (10) and a transcatheter artificial biological valve-in-ring (20), wherein the shape and structure of the transcatheter valve-in-ring anchoring stent (10) are matched with the real structure of the annuloplasty ring and supravalvular and infravalvular tissues after three-dimensional reconstruction based on imaging data of a patient who have undergone valve failure after implantation of a annuloplasty ring (30), the transcatheter valve-in-ring anchoring stent (10) is firstly delivered to the patient's failed annuloplasty ring for release, deformation and alignment with the supravalvular and infravalvular tissues of the failed annuloplasty ring; the transcatheter artificial biological valve-in-ring (20) is delivered to the transcatheter valve-in-ring anchoring stent (10) for release, the stent of the transcatheter artificial biological valve-in-ring (20) deforms and expands to the functional state of the transcatheter valve-in-ring, causing the transcatheter valve-in-ring anchoring stent (10) to deform again and combine with the expanded transcatheter valve-in-ring, and meanwhile, the re-deformation of the transcatheter valve-in-ring anchoring stent (10) causes the transcatheter valve-in-ring anchoring stent (10) to combine with the subvalvular structure again and anchor.

The present invention concerns an external aortic annuloplasty ring for positioning around the circumference of an aortic valve for external aortic root repair or stabilization of the annulus to support the aortic valve, wherein the ring is open-ended and thereby having two opposite open ends, wherein the ring comprises at least two sections with different elastic properties along the perimeter of the ring, and wherein said opposite open ends are suitable for being joined together, such as by suturing, so as to form a closed ring around the aortic root. The invention further concerns a method for manufacturing such a ring.